Finance

FDA says Guillain-Barre syndrome is possible risk of Pfizer’s RSV vaccine for older adults

February 24, 2023 admin-dominor Biotech and Pharmaceuticals, Biotechnology, Breaking News: Business, BUSINESS, business news, Centers for Disease Control and Prevention, coronavirus, Disease outbreaks, epidemics, FDA, GSK plc, Health care industry, Pandemics, Pfizer Inc, Politics, Respiratory syncytial virus, U.S. Economy, Vaccinations

The FDA sees a potential risk and has asked Pfizer to conduct a safety study on Guillain-Barre after a potential approval, which the company said it would do.

Source link

You May Also Like